Ardent Health (ARDT) is back in focus after a series of securities class action lawsuits tied to disclosures on accounts receivable accounting, higher professional liability reserves, and alleged weaknesses in financial reporting controls.
See our latest analysis for Ardent Health.
At the latest share price of $8.60, Ardent Health has seen a 41.5% decline in its 90 day share price return and a 39.01% fall in 1 year total shareholder return. Recent lawsuits appear to be keeping pressure on sentiment rather than supporting any rebound in momentum.
If this legal overhang has you thinking about diversification, it could be worth scanning other hospital operators and service providers via our healthcare stocks.
With securities lawsuits, a sharp 90 day sell off, and Ardent Health trading at $8.60 compared with an analyst price target of $13.23, you have to ask yourself: is this a reset buying opportunity, or is the market already pricing in future growth?
Most Popular Narrative: 38.4% Undervalued
Compared with the last close of $8.60, the most followed narrative points to a fair value of $13.96, putting a spotlight on potential future earnings power rather than recent legal and sentiment headwinds.
The analysts have a consensus price target of $19.273 for Ardent Health based on their expectations of its future earnings, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $23.0, and the most bearish reporting a price target of $12.0.
Curious what has to happen between now and 2028 for that fair value to hold up? Revenue, earnings and margins all play a part, as does the assumed earnings multiple on those profits. The full narrative lays out the growth path, profitability targets and discount rate behind that number.
Result: Fair Value of $13.96 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, persistent margin pressure from higher labor and professional fees, plus ongoing payer denials, could quickly challenge the claim that the stock is 38.4% undervalued.
Find out about the key risks to this Ardent Health narrative.
Another View: Our DCF Model Says Overvalued
The popular narrative leans on earnings power and a fair value of $13.96, but the Simply Wall St DCF model lands in a very different place. On that approach, Ardent Health’s fair value is $4.52, which implies the current $8.60 price screens as overvalued. Which story do you think holds up better?
Look into how the SWS DCF model arrives at its fair value.
ARDT Discounted Cash Flow as at Jan 2026
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ardent Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 873 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.
Build Your Own Ardent Health Narrative
If you look at the numbers and reach a different conclusion, or just prefer your own homework, you can build a custom view in minutes with Do it your way.
A great starting point for your Ardent Health research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
Looking for more investment ideas?
If you want to balance a focused view on Ardent Health with fresh opportunities, use the Simply Wall St Screener to quickly surface ideas that match your style.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com